
Mortality associated with heart failure (HF) has largely remained unchanged in the last 20 years, and one possible reason could be depression, according to Bruce Rollman, MD, MPH, of the University of Pittsburgh School of Medicine, who discussed results of a recent National Institutes of Health-supported study on the topic during a session titled, “Blended Collaborative Care for Treating HF and Comorbid Depression: 12-Month Primary Outcomes from the Hopeful Heart Trial” at the American College of Cardiology Annual Scientific Session.
A number of studies have shown that depression is highly comorbid in patients with HF. In this patient population, depression is associated with decreased health-related quality of life, decreased adherence with evidence-based care, and increased mortality, readmissions, and healthcare costs. However, depression is rarely recognized and treated in these patients.
The chronic care model has been used to treat other cardiac conditions and includes a team-based, proactive approach that includes guideline-based care. In the Hopeful Heart trial, the researchers assessed the application of this care model for depression and HF.